Canada Consults On Disclosure Of Confidential Info On Approved Products
This article was originally published in Clinica
Health Canada is seeking feedback on a draft guideline that explains how the health minister intends to use new discretionary powers to disclose confidential business information (CBI) about approved drugs and medical devices, without prior permission from affected companies, to help health researchers and practitioners in their work and to improve patient safety.
You may also be interested in...
US medtech industry association AdvaMed is concerned that Health Canada’s plan to proactively release certain clinical information in medical device applications could undercut innovation.
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.